Payment overview · 2025
General Payments
$102.01
5 reported records · 4 companies
Healthcare provider profile · identity verified
Joseph D Hope, DO
Allopathic & Osteopathic Physicians|Internal Medicine · MEDIA, PA · NPI 1699743377
Verified facts
What the public records show
CMS Open Payments records show Joseph D Hope, DO received $102.01 in general payments during 2025 across 5 reported records.
ARGENX US, INC. accounted for 29.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $30.00 | 29.4% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $29.35 | 28.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.77 | 22.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.89 | 19.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $102.01 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $42.66 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $30.00 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $29.35 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 725 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 661 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 578 | 72 |
| Escitalopram Oxalate | Escitalopram Oxalate | 523 | 41 |
| Eliquis | Apixaban | 488 | 48 |
| Gabapentin | Gabapentin | 456 | 43 |
| Donepezil Hcl | Donepezil Hcl | 452 | 31 |
| Sertraline Hcl | Sertraline Hcl | 449 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 417 | 52 |
| Furosemide | Furosemide | 411 | 50 |
| Famotidine | Famotidine | 409 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 360 | 40 |
| Trazodone Hcl | Trazodone Hcl | 296 | 30 |
| Mirtazapine | Mirtazapine | 280 | 30 |
| Potassium Chloride | Potassium Chloride | 278 | 32 |
| Omeprazole | Omeprazole | 255 | 33 |
| Lisinopril | Lisinopril | 233 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 25 |
| Simvastatin | Simvastatin | 211 | 23 |
| Memantine Hcl | Memantine Hcl | 186 | 13 |
| Xarelto | Rivaroxaban | 185 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 183 | 17 |
| Metformin Hcl | Metformin Hcl | 178 | 22 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 158 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 155 | 13 |
| Midodrine Hcl | Midodrine Hcl | 155 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 151 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 136 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 125 | 15 |
| Bupropion Xl | Bupropion Hcl | 115 | suppressed |
| Losartan Potassium | Losartan Potassium | 108 | 22 |
| Prednisone | Prednisone | 106 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 105 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 19 |
| Montelukast Sodium | Montelukast Sodium | 102 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | suppressed |
| Gemtesa | Vibegron | 94 | suppressed |
| Carvedilol | Carvedilol | 93 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 90 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 88 | suppressed |
| Valsartan | Valsartan | 85 | 11 |
| Allopurinol | Allopurinol | 84 | 11 |
| Memantine Hcl Er | Memantine Hcl | 82 | suppressed |
| Calcitriol | Calcitriol | 78 | suppressed |
| Ezetimibe | Ezetimibe | 78 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 12 |
| Risperidone | Risperidone | 70 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 65 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 13 |
| Diltiazem Hcl | Diltiazem Hcl | 59 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 59 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 39 |
| Entresto | Sacubitril/Valsartan | 54 | suppressed |
| Mupirocin | Mupirocin | 54 | 28 |
| Digoxin | Digoxin | 50 | suppressed |
| Latanoprost | Latanoprost | 47 | 13 |
| Atenolol | Atenolol | 43 | suppressed |
| Finasteride | Finasteride | 43 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 43 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Amantadine | Amantadine Hcl | 41 | suppressed |
| Olanzapine | Olanzapine | 40 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Nystatin | Nystatin | 39 | 22 |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 36 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 36 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 35 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 35 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 34 | suppressed |
| Loperamide | Loperamide Hcl | 33 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Colchicine | Colchicine | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Rytary | Carbidopa/Levodopa | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | 22 |
| Spironolactone | Spironolactone | 31 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 30 | suppressed |
| Mirabegron Er | Mirabegron | 29 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 29 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Ursodiol | Ursodiol | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Letrozole | Letrozole | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Repaglinide | Repaglinide | 23 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 21 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 21 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 14 |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 13 |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | 11 |
| Morphine Sulfate | Morphine Sulfate | 16 | 15 |
| Restasis | Cyclosporine | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Hydroxyurea | Hydroxyurea | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $102.01 · 5 records | ARGENX US, INC. | NUPLAZID, REXULTI, VYVGART HYTRULO | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error